GSK's Fluticasone Furoate/Umeclidinium/Vilanterol Inhalation Powder Approved for Maintenance Treatment of Adult Asthma in China

Source: Shell Finance

Beijing News (Reporter Wang Kala) On January 23, GSK announced that the National Medical Products Administration had approved a new indication for Trelegy (Fluticasone Furoate/Umeclidinium/Vilanterol Inhalation Powder, FF/UMEC/VI) for maintenance treatment in adult asthma patients. The approval of this new indication expands the original chronic obstructive pulmonary disease (COPD) indication for Trelegy, making Fluticasone Furoate/Umeclidinium/Vilanterol Inhalation Powder the first and only triple therapy in China currently available for maintenance treatment of both asthma and COPD using a single inhaler device.

Fluticasone Furoate/Umeclidinium/Vilanterol Inhalation Powder is a once-daily, triple therapy delivered via a single inhalation device. It contains three components: the inhaled corticosteroid (ICS) fluticasone furoate (FF), the long-acting muscarinic antagonist (LAMA) umeclidinium (UMEC), and the long-acting beta2-adrenergic agonist (LABA) vilanterol trifenatate (VI). The medication is administered through GSK's proprietary Ellipta dry powder inhaler. In 2019, Trelegy was first approved in China for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Asthma is one of the most common chronic respiratory diseases. Despite clear treatment guidelines, approximately half of the patients still do not have their symptoms effectively controlled, which not only increases the risk of acute attacks but also affects the quality of life for patients.

Dr. Kaivan Khavandi, Senior Vice President of GSK's Global Respiratory, Immunology and Inflammation Research and Development, stated that for suitable adult asthma patients with uncontrolled symptoms, early initiation of single-inhaler triple therapy can help improve clinical outcomes. The approval of this new indication provides an important treatment option for adult patients who have not yet achieved optimal disease control and are therefore at risk of acute exacerbations.

Proofread by Baoqing Liu